Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
July 31 2008 - 4:00PM
PR Newswire (US)
SEATTLE, July 31 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals
Inc. (NASDAQ:TRBN) today announced that it plans to issue earnings
results for second quarter and first six months ended June 30,
2008, after the close of market on Aug. 7, 2008. The company's
earnings conference call will take place Aug. 7, 2008, at 2 p.m.
PDT (5 p.m. EDT). Both live events will be available for viewing on
Trubion's website at http://investors.trubion.com/events.cfm.
Second Quarter and First Six Months Earnings Conference Call: 2
p.m. PDT / 5 p.m. EDT, Aug. 7, 2008 Trubion will host a conference
call and webcast to discuss its second quarter and six months 2008
financial results. The call will be held Aug. 7 at 2 p.m. Pacific
time (5 p.m. Eastern time). The live event will be available from
Trubion's website at http://investors.trubion.com/events.cfm, or by
calling 1 (719) 325-4916 or 1 (877) 397-0292. A replay of the
discussion will be available from Trubion's website or by calling 1
(719) 457-0820 or 1 (888) 203-1112 and entering 6969493. Replay
will be available at 8 p.m. EDT until midnight, Aug. 14, 2008. The
webcast replay will be available in the events section of Trubion's
website. About Trubion Trubion is a biopharmaceutical company that
is creating a pipeline of novel protein therapeutic product
candidates to treat autoimmune and inflammatory diseases and
cancer. The company's mission is to develop a variety of
first-in-class and best-in-class product candidates, customized for
optimal safety, efficacy, and convenience that it believes may
offer improved patient experiences. Trubion's current product
candidates are novel single-chain protein, or SMIP(TM),
therapeutics, and are designed using its custom drug assembly
technology. Trubion's product pipeline includes CD20-directed
candidates such as TRU-015 and SBI-087 for autoimmune and
inflammatory diseases, developed under the company's Wyeth
collaboration. Trubion's product pipeline also includes Trubion's
proprietary product candidate, TRU-016, a novel CD37-targeted
therapy for the treatment of B-cell malignancies that is currently
in Phase 1/2 clinical evaluation. In addition to Trubion's current
product candidates, the company is also developing additional
alliance and proprietary product candidates that build on its
product development experience. More information is available in
the investors section of Trubion's website: investors.trubion.com.
TRBN-G DATASOURCE: Trubion Pharmaceuticals Inc. CONTACT: Jim
DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500, ; or Amy Petty, Senior
Account Executive, Waggener Edstrom Worldwide Healthcare,
+1-617-576-5788, , for Trubion Pharmaceuticals Inc. Web site:
http://www.trubion.com/
Copyright
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jul 2023 to Jul 2024